EZH2-IN-17 is a potent, orally active EZH2 inhibitor with an IC50 of 0.95 nM; it exhibits high antiproliferative activity against various lymphoma cell lines, including WSU-DLCL2, Pfeiffer, and Karpas-422, with IC50 values of 2.36 nM, 1.73 nM, and 1.82 nM, respectively.